FDA Grants Accelerated Approval to Inovio’s Voceryq

The US Food and Drug Administration has granted accelerated approval to Inovio’s Voceryq, according to Thepharmaletter. The product was previously referred to as INO-3107.

Thepharmaletter reported that Inovio announced the FDA action on Friday. Voceryq is identified in the report as doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd.

Accelerated approval for adults with RRP

According to Thepharmaletter, Voceryq received accelerated approval to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, or RRP.

The reported FDA action is specifically for adults with RRP and is focused on reducing surgery frequency. Thepharmaletter described the regulatory pathway as accelerated approval.

Inovio’s announcement places Voceryq within a defined FDA-approved use: reducing the frequency of surgery in the adult RRP population named in the report. The reported decision does not change the need for communications to remain aligned with the approved-use language cited by Thepharmaletter.

Key details from the announcement

• Company: Inovio
• Product: Voceryq
• Previous name: INO-3107
• Regulatory agency: US Food and Drug Administration
• Regulatory action: Accelerated approval
• Population: Adults with recurrent respiratory papillomatosis
• Reported use: Reducing the frequency of surgery

Discussion focus for pharmaceutical and biotech sales professionals

For medical sales professionals following regulatory developments, the announcement provides a clear milestone involving Inovio and Voceryq. The central points reported by Thepharmaletter are the FDA’s accelerated approval, the adult RRP population, and the stated goal of reducing surgery frequency.

Educational conversations about the news can distinguish Voceryq from its prior reference name, INO-3107, while accurately characterizing the FDA action as accelerated approval. The reported indication should remain limited to the adults with recurrent respiratory papillomatosis described in the announcement.

Thepharmaletter’s report identifies both the product’s full name and its prior development reference, providing context for professionals who may encounter either name in discussions of the FDA decision.